key: cord-0025836-4jqcl0ny
authors: Curley, Rachael; Campbell, Michael J; Walters, Stephen J; Hoo, Zhe Hui; Wildman, Martin J
title: Regarding the articles on home spirometry
date: 2022-01-15
journal: J Cyst Fibros
DOI: 10.1016/j.jcf.2022.01.002
sha: 5bacfca63b11318e9788197ca3005a1135138956
doc_id: 25836
cord_uid: 4jqcl0ny

nan

Dear Editor , Home spirometry is increasingly used, in part due to the need for social distancing during the Covid-19 pandemic. We read with interest two recent JCF articles that evaluate home spirometry.

Paynter et al. [1] performed a secondary analysis of a home monitoring trial (eICE) comparing home and clinic spirometry. The eICE trial has a 12-month follow-up and ran from October 2011 to July 2015. The secondary analysis included 133 adolescents and adults (mean age 27 years, SD 12; mean baseline clinic ppFEV 1 78.9, SD 22.0) randomized to the early intervention arm. Home spirometry was performed unsupervised with AM2 + ® Lung Function Monitor (ERT). Cross-sectional comparison of paired readings within 7 days showed home FEV 1 was 70 ml lower (limits of agreement -972 ml to 832 ml). Mixed model with a cubic spline function for time was suggested as the most appropriate method for longitudinal analysis. Mean ppFEV 1 change was -2.0 (95% CI -4.3 to 0.2) with home spirometry versus -3.0 (95% CI -4.1 to -1.9) with clinic spirometry. The wider confidence interval indicates lower precision for home spirometry.

Bell et al. [2] performed a single-center prospective observational study comparing observed and unobserved home spirometry among 74 adults (mean age 37 years, SD 11; mean ppFEV 1 59) between February and December 2020. In contrast with Paynter et al., there was no 'gold standard' clinic spirometry, hence the study findings may be more difficult to interpret. Home spirometry was performed with Air-Next TM (NuvoAir) or Spirohome TM (Inofab). Unsupervised spirometry was performed within 24 h prior to remote clinic consultation. During remote consultations, a respiratory scientist supervised the spirometry using video conferencing. Paired FEV 1 from 53 adults during their most recent clinic visit showed a mean difference of 0.7 ml. However, the limits of agreement (-220 ml to 220 ml) for the same adult on separate occasions (observed versus unobserved) exceeds the ATS/ERS repeatability criteria for FEV 1 of 150 ml [3] .

These studies raise the concern that home spirometry, especially unsupervised, may lack precision for both cross-sectional and longitudinal analyses. Many centers will now be accumulating experience with home spirometry. Our single-center prospective study is an example of smaller datasets that can emerge from clinical care in individual centers, and also identified that home spirometry may lack precision in comparison to clinic spirome-try. Data were collected between June 2015 and July 2016 from 17 adults (26 paired readings; mean age 31 years, SD 7; mean clinic ppFEV 1 67.9, SD 21.3). Clinic spirometry was performed by lung physiologists using MicroLab ML3500 MK8 (Carefusion). Home spirometry was performed unsupervised within 3 days of clinic using Lung monitor USB model 40 0 0 (Vitalograph). Crosssectional FEV 1 comparison with random effects model fitted to account for multiple paired readings found an adjusted mean difference of 111 ml in favor of clinic spirometry (limits of agreement -299 ml to 76 ml), see Fig. 1 .

In a research setting, lack of precision may mean that larger sample sizes are required in studies only using home spirometry to achieve similar statistical power as studies using clinic spirometry. Studies using both clinic and home spirometry may achieve optimal precision by analyzing the readings separately, since current evidence suggest that the readings are not necessarily interchangeable.

The lack of precision with home spirometry also presents challenges to clinical use. As CF prognosis improved, the rate of FEV 1 decline has gradually reduced. Highly efficacious CFTR modulators are now widely available and further attenuation of FEV 1 decline is now possible. The Canadian CF registry analysis found a mean annual ppFEV 1 change of only -0.3 (95% CI -0.9 to 0.3) following the initiation of Ivacaftor among those with gating mutations [4] . Such subtle FEV 1 decline is difficult to measure, even with clinic spirometry. More sensitive measures of lung health are required in the post-modulator era, and imprecise home spirometry is unlikely to be the solution. Home spirometry may miss important decline in lung health, resulting in clinicians being falsely reassured and failing to institute treatments that are necessary for maintaining lung health.

The recent studies in JCF suggest that home spirometry readings may be lacking in precision compared to clinic spirometry. This applies to both cross-sectional and longitudinal analyses of FEV 1 data. Whilst it may be tempting to assume that home spirometry readings can replace clinic spirometry, further studies are required to understand and optimize the precision of home spirometry FEV 1 readings. The precision of spirometry readings is particularly pertinent in the post-modulator era, where precisely identifying annual ppFEV 1 change of 1.0 or less is critical to realizing the full benefit of highly efficacious CFTR modulators and achieving a normal life-expectancy among people with CF. 

Home spirometry for this study was funded by Profile Pharma Ltd. The funder has no role in study design, analysis, interpretation or decision to publish.

R Curley received funding from Profile Pharma Ltd for home spirometry. There is no other competing interests to disclose. 

A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis

Quality of home spirometry performance amongst adults with cystic fibrosis

Real-world use of ivacaftor in Canada: a retrospective analysis using the Canadian Cystic Fibrosis Registry